An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1258-1270

  Fridman, Arthur ^a   Finnefrock, Adam C ^a   Peruzzi, Daniela ^b,c   Pak, Irene ^a   Monica, Nicola La ^b,d   Bagchi, Ansuman ^a   Casimiro, Danilo R ^a   Ciliberto, Gennaro ^b,e   Aurisicchio, Luigi ^b,f,g  

^a MERCK RESEARCH LABORATORIES   (United States)

^b IRBM   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HYBRIDON INC   (United States)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Grande Ospedale Metropolitano   (Italy)

^g Takis srl   (Italy)

Author keywords

Cancer vaccine; CEA; Epitope prediction; HER2 neu; TERT

Indexed keywords

BETA 2 MICROGLOBULIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TELOMERASE REVERSE TRANSCRIPTASE;

ACCURACY; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CD8+ T LYMPHOCYTE; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOGENICITY; INFORMATION PROCESSING; INFORMATION RETRIEVAL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84876497232     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21355     Document Type: Article

References (62)

1. Rammensee HG, Falk K, Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11:213-44; PMID:8476560; http://dx.doi.org/10.1146/annurev.iy.11.040193.001241.
2. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528-30; PMID:7518614; http://dx.doi.org/10.1126/science.7518614.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7; PMID:9500606; http://dx.doi.org/10.1038/nm0398-321.
4. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligandmediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002; 168:3484-92; PMID:11907109.
5. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/science.1129003.
6. Bachinsky MM, Guillen DE, Patel SR, Singleton J, Chen C, Soltis DA, et al. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun 2005; 5:6; PMID:15779886.
7. Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008; 20:1057-66; PMID:18567615; http://dx.doi.org/10.1093/intimm/dxn063.
8. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156:3308-14; PMID:8617954.
9. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLAA* 0201-binding affinity. J Immunol 2001; 167:787-96; PMID:11441084.
10. Huang EH, Kaufman HL. CEA-based vaccines. Expert Rev Vaccines 2002; 1:49-63; PMID:12908512; http://dx.doi.org/10.1586/14760584.1.1.49.
11. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010; 59:1295-312; PMID:20532501; http://dx.doi.org/10.1007/s00262-010-0869-2.
12. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673-9; PMID:10403642; http://dx.doi.org/10.1016/S1074-7613(00)80066-7.
13. Marsh SGE, Parham P, Barber LD. The HLA FactsBook 2000. Elsevier Ltd. 416 pp.
14. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191:795-804; PMID:10704461; http://dx.doi.org/10.1084/jem.191.5.795.
15. Theobald M, Biggs J, Hernández J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185:833-41; PMID:9120389; http://dx.doi.org/10.1084/jem.185.5.833.
16. Grossmann ME, Davila E, Celis E. Avoiding Tolerance Against Prostatic Antigens With Subdominant Peptide Epitopes. J Immunother 1991; 24:237-41; http://dx.doi.org/10.1097/00002371-200105000-00007.
17. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998; 59:1-14; PMID:9544234; http://dx.doi.org/10.1016/S0198-8859(97)00255-3.
18. Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008; 26:4418-25; PMID:18802154; http://dx.doi.org/10.1200/JCO.2008.16.6462.
19. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006; 18:565-71; PMID:16919437; http://dx.doi.org/10.1016/j.ceb.2006.08.008.
20. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999; 59:431-5; PMID:9927058.
21. Tanaka H, Tsunoda T, Nukaya I, Sette A, Matsuda K, Umano Y, et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br J Cancer 2001; 84:94-9; PMID:11139320; http://dx.doi.org/10.1054/bjoc.2000.1547.
22. Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 1995; 84:298-303; PMID:7751006.
23. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002; 168:5900-6; PMID:12023395.
24. Menez-Jamet J, Kosmatopoulos K. Development of optimized cryptic peptides for immunotherapy. IDrugs 2009; 12:98-102; PMID:19204883.
25. Wulf M, Hoehn P, Trinder P. Identification of human MHC class I binding peptides using the iTOPIA-epitope discovery system. Methods Mol Biol 2009; 524:361-7; PMID:19377958; http://dx.doi.org/10.1007/978-1-59745-450-6_26.
26. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pérarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185:2043-51; PMID:9182675; http://dx.doi.org/10.1084/jem.185.12.2043.
27. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, et al. A general strategy to enhance immunogenicity of low-affinity HLAA2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000; 30:3411-21; PMID:11093159; http://dx.doi.org/10.1002/1521-4141(2000012)30:12<3411::AIDIMMU3411> 3.0.CO;2-R.
28. Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 2008; 4:2; PMID:18221540; http://dx.doi.org/10.1186/1745-7580-4-2.
29. Fridman A, Bagchi A, Bailey W. System and method for automated selection of T-cell epitopes. 2010. United States Patent 7756644.
30. Sette A, Keogh E, Ishioka G, Sidney J, Tangri S, Livingston B, et al. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Investig Drugs 2002;3:132-9;PMID:12054064.
31. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163-75; PMID:8254189.
32. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9; PMID:10602881; http://dx.doi.org/10.1007/s002510050595.
33. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 1994; 91:2105-9; PMID:7510885; http://dx.doi.org/10.1073/pnas.91.6.2105.
34. Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003; 12:1007-17; PMID:12717023; http://dx.doi.org/10.1110/ps.0239403.
35. Peters B, Bui HH, Frankild S, Nielson M, Lundegaard C, Kostem E, et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol 2006; 2:e65; PMID:16789818; http://dx.doi.org/10.1371/journal.pcbi.0020065.
36. Anthony DD, Lehmann PV. T-cell epitope mapping using the ELISPOT approach. Methods 2003; 29:260-9; PMID:12725791; http://dx.doi.org/10.1016/S1046-2023(02)00348-1.
37. Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 2002; 32:213-22; PMID:11782012; http://dx.doi.org/10.1002/1521-4141(200201)32:1<213::AIDIMMU213> 3.0.CO;2-8.
38. Buchsbaum S, Barnea E, Dassau L, Beer I, Milner E, Admon A. Large-scale analysis of HLA peptides presented by HLA-Cw4. Immunogenetics 2003; 55:172-6; PMID:12750860; http://dx.doi.org/10.1007/s00251-003-0570-0.
39. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 2001; 53:87-94; PMID:11345595; http://dx.doi.org/10.1007/s002510100300.
40. Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, et al. Immunogenic HLAB7-restricted peptides of hTRT. Int Immunol 2006; 18:1707-18; PMID:17077179; http://dx.doi.org/10.1093/intimm/dxl105.
41. Schatz MM, Peters B, Akkad N, Ullrich N, Martinez AN, Carroll O, et al. Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol 2008; 180:3210-7; PMID:18292545.
42. York IA, Brehm MA, Zendzian S, Towne CF, Rock KL. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci U S A 2006; 103:9202-7; PMID:16754858; http://dx.doi.org/10.1073/pnas.0603095103.
43. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004; 199:905-15; PMID:15067030; http://dx.doi.org/10.1084/jem.20031982.
44. Ishihara Y, Harada M, Azuma K, Tamura M, Shomura H, Fujii T, et al. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients. Int J Oncol 2004; 24:967-75; PMID:15010837.
45. Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, et al. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 2001; 31:3261-70; PMID:11745343; http://dx.doi.org/10.1002/1521-4141(200111)31:11<3261::AIDIMMU3261> 3.0.CO;2-4.
46. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157:2539-48; PMID:8805655.
47. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008; 105:3849-54; PMID:18319339; http://dx.doi.org/10.1073/pnas.0800080105.
48. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113:425-33; PMID:14755339.
49. Aurisicchio L, Scarselli E, La Monica N, Ciliberto G, Fridman A, Pak I, et al. T-Cell Peptide Epitopes from Carcinoembryonic Antigen, Immunogenic Analogs, and uses Thereof. 2008.
50. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, et al. Peptides derived from a wildtype murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159:1336-43; PMID:9233630.
51. Gritzapis AD, Perez SA, Baxevanis CN, Papamichail M. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo. Br J Cancer 2005; 92:72-9; PMID:15583693; http://dx.doi.org/10.1038/sj.bjc.6602259.
52. Combet C, Blanchet C, Geourjon C, Deléage G. NPS@: network protein sequence analysis. Trends Biochem Sci 2000; 25:147-50; PMID:10694887; http://dx.doi.org/10.1016/S0968-0004(99)01540-6.
53. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74:929-37; PMID:8104103; http://dx.doi.org/10.1016/0092-8674(93)90472-3.
54. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, et al. Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994; 152:3913-24; PMID:8144960.
55. Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, et al. Prominent roles of secondary anchor residues in peptide binding to HLAA24 human class I molecules. J Immunol 1995; 155:4307-12; PMID:7594589.
56. Rammensee HG, Friede T, Stevanoviíc S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41:178-228; PMID:7890324; http://dx.doi.org/10.1007/BF00172063.
57. Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, et al. H-2 class I knockout, HLAA2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999; 29:3112-21; PMID:10540322; http://dx.doi.org/10.1002/(SICI)1521-4141(199910)29:10<3112::AIDIMMU3112> 3.0.CO;2-Q.
58. Giannetti P, Facciabene A, La Monica N, Aurisicchio L. Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J Immunol Methods 2006; 316:84-96; PMID:17010367; http://dx.doi.org/10.1016/j.jim.2006.08.004.
59. Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004; 172:4575-82; PMID:15034075.
60. Mennuni C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005; 117:444-55; PMID:15906358; http://dx.doi.org/10.1002/ijc.21188.
61. Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, et al. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther 2009; 17:1804-13; PMID:19623161; http://dx.doi.org/10.1038/mt.2009.165.
62. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005; 113:67-77; PMID:15386429; http://dx.doi.org/10.1002/ijc.20536.